arrow
M

Mark E. Dudley

University of Pennsylvania
H指数:67
被引数:4.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes
2023-11-074
OAAI
INITIAL SAFETY, EFFICACY, AND PRODUCT ATTRIBUTES FROM THE SURPASS TRIAL WITH ADP-A2M4CD8, A SPEAR T-CELL THERAPY INCORPORATING AN AFFINITY OPTIMIZED TCR TARGETING MAGE-A4 AND A CD8a αCO-RECEPTOR
2020-11-0910
PREAI
Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response

CD19 car-t细胞的单细胞多重细胞因子分析揭示了多功能抗原特异性反应的多样性

2017-11-21116
OAAI
Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2015-05-14322
OAAI
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

使用NY-ESO-1-Reactive T细胞受体基因工程淋巴细胞的试点试验: 长期随访和与反应相关

2015-03-01702
OAAI
TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients

TIL疗法扩大了黑色素瘤患者的肿瘤反应性CD8 T细胞区室

2014-10-27157
OAAI
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
2013-02-011.0K
OAAI
IRF5 gene polymorphisms in melanoma
2012-08-2133
OAAI